ALEJANDRO ALVA: Open Payments
NPI 1801816764 · COSTA MESA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$77,471 in 268 payments from 23 companies in 2025. Trend: 2023 $41,027 · 2024 $62,909 · 2025 $77,471
Speaker / faculty: $46,678Consulting: $16,750Food & beverage: $7,982Travel & lodging: $6,056Education: $5
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 56 | $37,716 |
| Teva Pharmaceuticals USA, Inc. | 36 | $18,247 |
| Alkermes, Inc. | 16 | $8,733 |
| Neurocrine BioSciences, Inc. | 35 | $8,523 |
| Axsome Therapeutics, Inc. | 13 | $1,001 |
| ABBVIE INC. | 31 | $689 |
| Janssen Pharmaceuticals, Inc | 12 | $421 |
| Luye Pharma (USA) Ltd. | 8 | $386 |
| Otsuka America Pharmaceutical, Inc. | 6 | $320 |
| Lundbeck LLC | 16 | $293 |
Products named: CAPLYTA, AUSTEDO XR, INGREZZA, LYBALVI, Auvelity, VRAYLAR, REXULTI, ERZOFRI EXTENDED-RELEASE.
Industry payments across CA — which companies pay providers there.
